ArticleFrontiers in pharmacology2025
Intranasal Galanin (1-15) modulates alcohol self-administration and depressive-like behavior in rats and shows a favorable safety profile.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Intranasal Galanin(1-15) influences depression- and anxiety-related behaviors through sex-dependent mechanisms in rats.Biology of sex differences · 2026Article
- Intranasal Drug Delivery in Neuropharmacology: Advances in Brain-Targeted Therapies and Bioethical Challenges.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Galanin is a neuropeptide in the central nervous system that regulates mood and alcohol consumption. Its N-terminal fragment, Galanin (1-15) [GAL (1-15)], has demonstrated specific behavioral effects, enhancing the efficacy of selective serotonin reuptake inhibitors (SSRIs) and reducing ethanol intake and alcohol self-administration in preclinical models. Additionally, GAL (1-15) combined with SSRIs decreases alcohol self-administration and depressive symptoms in a comorbid alcoholism-depression model. These findings suggest potential applications in the treatment of depression and alcohol use disorders. Given its therapeutic potential, evaluating the translational aspects and safety of GAL (1-15) is essential for clinical development. Methods: This study investigated the intranasal administration of GAL (1-15), assessing its effects on depression-related behavior in the Forced Swim Test (FST) and alcohol self-administraation in an operant selfadministration model. To determine its safety profile, we evaluated GAL (1-15) for cardio toxicity (hERG channel inhibition), genotoxicity (micronucleus formation), and drug interactions (CYP450 inhibition). Results: Results showed that intranasal GAL (1-15) exhibited a prodepressant effect, as previously demonstrated with its ICV administration. Furthermore, intranasal GAL (1-15) effectively reduced alcohol consumption. In vitro safety assessments revealed no adverse effects on cardiac function or genotoxicity at the concentrations studied, with minimal interaction with CYP450 enzymes, supporting its suitability for drug development. Discussion: In conclusion, intranasal administration of GAL (1-15) represents a promising candidate for clinical trials due to its favorable safety profile and therapeutic potential. Its use appears particularly suitable as a standalone treatment for alcohol use disorder and, when combined with SSRIs, as a potential therapy for depressive disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.